Skip to main content

Case Studies

At REPROCELL, we've helped hundreds of clients advance their novel therapeutics – including researchers from 24 of the top 25 Pharma companies.

The case studies below highlight some of our most prominent success stories to date. If you do not see your tissue type mentioned below, make an inquiry — our human tissue experts will be happy to share example data across a range of tissue types and endpoints.

IPM

Lindsey and Amna at microscopes

Achieve regulatory approval

When IPM approached the regulators for approval of their HIV prevention ring, they requested additional data on uterine contractility. Find out how our studies in fresh human uterine tissue helped IPM gain approval.

Amgen

skin biopsies

Avoid species differences

Read our case study on Amgen's publication, which highlights the useful comparisons that can be made between matched tissues from preclinical species and humans.

Roche

Pipetting at wire myographs

Eliminate clinical adverse effects

Adverse effects may go undetected during preclinical safety assessments and only become apparent during clinical trials. In most cases, such adverse effects in humans were not observed in animal models.

Bionorica

Michael at wire myographs

Evaluating spasmolytic effects of BNO 1095

REPROCELL supported Bionorica in advancing BNO 1095, a plant-based treatment for primary dysmenorrhea, through human tissue studies demonstrating its spasmolytic effects.

GI Health Pharma

intestinal-motility

Investigating the Mechanism of Action of a GC-C Agonist Using Human Intestinal Tissue

This study shows that GC-C agonists activate a cGMP-dependent signalling pathway in human intestinal tissue that modulates ion transport—reducing sodium absorption while increasing chloride secretion—thereby driving fluid secretion. It highlights how this coordinated regulation of epithelial transporters (including CFTR and NHE3) helps explain the therapeutic effects of GC-C agonists in gastrointestinal disorders. 

NeurAxon

Wire myograph drawing

Vascular Safety of a Selective nNOS Inhibitor in Human Resistance Arteries

A selective nNOS inhibitor was evaluated in human resistance arteries and demonstrated no adverse effects on vascular contractility or vasoreactivity, providing strong evidence of a favourable vascular safety profile and supporting its continued development.

CV Therapy Pharma

Coronary arteries assays

Human Cardiac and Vascular Effects of Anti-Arrhythmic Drugs

Using isolated human cardiac and vascular tissues, REPROCELL demonstrated the direct effects of vernakalant and flecainide on contractility and vascular tone, providing mechanistic insight into their haemodynamic effects. 

Equillium

undefined-Jul-10-2026-03-37-44-6921-PM

Demonstrating AhR Target Engagement in Human Intestinal Tissue

Using human-derived intestinal tissues, REPROCELL demonstrated robust target engagement of an AhR modulator, providing translational evidence of pathway activation and supporting progression into clinical development.

Contact our experts